March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
February 2026 in “Journal of Cutaneous and Aesthetic Surgery” Most emerging dermatological treatments lack strong evidence and require more research.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
December 2025 in “Reports — Medical Cases Images and Videos” Discoid lupus erythematosus can be mistaken for a skin infection, complicating diagnosis and treatment.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
October 2025 in “Pharmaceutics” Microneedles improve drug delivery for skin diseases, enhancing treatment effectiveness and patient compliance.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
September 2025 in “Value in Health” September 2025 in “International Journal of Molecular Sciences” International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
July 2025 in “JOJ Dermatology & Cosmetics” Both treatments improved hair quality and thickness equally, with mild side effects.
July 2025 in “Actas Dermo-Sifiliográficas” Trichodynia is a challenging scalp condition to treat, needing gentle care and more research for better solutions.
June 2025 in “Dermatopathology” Dupilumab and COVID-19 can worsen or trigger psoriasis.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
Advancements in diagnostics, treatments, and technology have improved hair loss detection and restoration, with some types being reversible.
Alopecia Areata causes hair loss and needs treatments that address both physical and emotional health.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
August 2024 in “Journal of the Association of Physicians of India” Adding vitamin B12 to food like salt can effectively improve vitamin levels in rural areas.
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
April 2024 in “International journal of molecular sciences” Combination pharmacotherapy is generally more effective for treating keloids and hypertrophic scars.
Light exposure is crucial for health, helping prevent and treat illnesses.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
January 2024 in “Medicinska istrazivanja” Timely treatment of EPDS can reduce scarring.
September 2023 in “Irish Journal of Medical Science (1971 -)” About 61% of women who had COVID-19 experienced hair loss afterward.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
August 2023 in “Authorea (Authorea)” Tinea capitis should be considered in adults with scalp issues for proper treatment.
Most postmenopausal women experience significant skin changes and various skin conditions.